Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

NCT01173679 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT01173679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01173679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2010
Completion date
January 31, 2015
Enrollment
10 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, small lymphocytic lymphoma